This happens through MAMPs, which then activate the critical downstream signaling pathways, like STAT3 and NF-kB pathways, as well as the ERK and PI3K pathways—regulating cell proliferation, survival, and differentiation—which are upregulated in lung cancer patients [94]. Here, NFKB1 is linked to lung carcinoma.